Trinity Biotech Welcomes Perceptive Advisor’s Indication of Potential Debt-to-Equity Conversion - Strengthening Balance Sheet and Supporting Growth
Trinity Biotech (Nasdaq: TRIB) on October 27, 2025 welcomed an indicated proposal from its largest investor and primary lender, Perceptive Advisors, to convert a portion of outstanding debt and other obligations into equity.
The company said the proposed equitization, if implemented, could strengthen the balance sheet, enhance financial flexibility and support its growth objectives while the company engages in discussions with Perceptive and other stakeholders. The release also reiterates standard forward-looking statement cautions and lists risks that could affect outcomes.
Trinity Biotech (Nasdaq: TRIB) il 27 ottobre 2025 ha accolto una proposta indicata dal suo maggior investitore e prestatore principale, Perceptive Advisors, di convertire una parte del debito in essere e altre obbligazioni in capitale.
L'azienda ha detto che l'equitalizzazione proposta, se attuata, potrebbe rafforzare il bilancio, migliorare la flessibilità finanziaria e sostenere i suoi obiettivi di crescita mentre l'azienda conduce colloqui con Perceptive e altri soggetti interessati. Il comunicato richiama anche i normali avvertimenti relativi alle dichiarazioni previsionali e indica i rischi che potrebbero influenzare i risultati.
Trinity Biotech (Nasdaq: TRIB) el 27 de octubre de 2025 dio la bienvenida a una propuesta indicada por su mayor inversor y prestamista principal, Perceptive Advisors, para convertir una parte de la deuda pendiente y otras obligaciones en capital.
La empresa dijo que la equitización propuesta, si se implementa, podría fortalecer el balance, mejorar la flexibilidad financiera y apoyar sus objetivos de crecimiento mientras la empresa mantiene conversaciones con Perceptive y otros stakeholders. El comunicado también reitera las advertencias habituales sobre declaraciones a futuro y enumera los riesgos que podrían afectar los resultados.
트리니티 바이오테크(나스닥: TRIB)는 2025년 10월 27일, 최대 투자자이자 주요 대주인 Perceptive Advisors의 권고안에 따라 발행된 부채의 일부 및 기타 채무를 지분으로 전환하는 제안을 환영했습니다.
회사 측은 제안된 주식전환이 실행될 경우 대차대조표를 강화하고, 재무 유연성을 향상시키며, Perceptive 및 기타 이해관계자들과의 논의와 함께 성장 목표를 지원할 수 있다고 밝혔습니다. 또한 발표는 일반적인 향후 예측 진술에 대한 주의사항을 재확인하고 결과에 영향을 미칠 수 있는 위험 요소를 나열합니다.
Trinity Biotech (Nasdaq : TRIB) a accueilli le 27 octobre 2025 une proposition énoncée par son plus grand investisseur et prêteur principal, Perceptive Advisors, visant à convertir une partie de la dette en cours et d'autres obligations en actions.
La société a déclaré que l'équité proposée, si elle est mise en œuvre, pourrait renforcer le bilan, améliorer la flexibilité financière et soutenir ses objectifs de croissance pendant que l'entreprise discute avec Perceptive et d'autres parties prenantes. Le communiqué rappelle également les avertissements habituels concernant les déclarations prospectives et énumère les risques qui pourraient affecter les résultats.
Trinity Biotech (Nasdaq: TRIB) hat am 27. Oktober 2025 einen von ihrem größten Investor und Hauptgläubiger, Perceptive Advisors, vorgelegten Vorschlag begrüßt, einen Teil der ausstehenden Schulden und anderer Verpflichtungen in Eigenkapital umzuwandeln.
Das Unternehmen sagte, dass die vorgeschlagene Gleichstellung, falls umgesetzt, die Bilanz stärken, die finanzielle Flexibilität verbessern und seine Wachstumsziele unterstützen könnte, während das Unternehmen Gespräche mit Perceptive und anderen Stakeholdern führt. Die Mitteilung bekräftigt auch die üblichen Warnhinweise zu zukunftsgerichteten Aussagen und führt Risiken auf, die die Ergebnisse beeinflussen könnten.
Trinity Biotech (ناسداك: TRIB) رحَّبت في 27 أكتوبر 2025 باقتراح مُبين من أكبر مستثمريها ومُقرِضها الرئيسي Perceptive Advisors يقضي بتحويل جزء من الدين المستحق والالتزامات الأخرى إلى أسهم.
قالت الشركة إن التسييل المقترح للأسهم، إذا تم تنفيذه، يمكن أن يُقوّي الميزانية، يعزز المرونة المالية ويدعم أهداف نموها بينما تجري مناقشات مع Perceptive وأصحاب المصلحة الآخرين. كما يؤكد البيان التحذيرات المعتادة بخصوص التصريحات المستقبلية ويذكر المخاطر التي قد تؤثر على النتائج.
Trinity Biotech (纳斯达克：TRIB) 于2025年10月27日欢迎了其最大投资者及主要贷款方Perceptive Advisors提出的一项将部分未偿债务及其他义务转换为股本的建议。
公司表示，如实施该拟议的股权化，可能强化资产负债表、提升财务灵活性并在公司与Perceptive及其他利益相关方进行磋商的同时支持其增长目标。公告还重申了关于前瞻性陈述的通常警告，并列出可能影响结果的风险。
- None.
- None.
Insights
Debt-to-equity proposal from largest lender could materially reduce leverage and improve financial flexibility if completed.
Trinity Biotech received an indicated proposal from its largest investor and primary lender, Perceptive Advisors, to convert a portion of outstanding debt and other obligations into equity; management describes the initiative as intended to strengthen the balance sheet and support growth.
The business mechanism is straightforward: converting debt into equity reduces cash interest burden and lowers leverage, which can free up operating cash and enlarge runway without immediate cash raises. This change also alters the company’s capital structure by increasing equity claims and diluting existing holders; both effects are stated or implied by the conversion concept.
Key dependencies and risks include successful negotiation and implementation of the proposal, agreement among stakeholders, and any required approvals or Nasdaq listing conditions; the company explicitly flags continued listing on the Nasdaq as a risk area. Execution risk is the primary uncertainty because the announcement describes an indicated intention and future proposal rather than a completed transaction.
Monitor the formal proposal, the portion of debt targeted for equitization, any shareholder or creditor votes, and public filings that record definitive terms; expect these items to surface before the market can fully price the effect. The near-term horizon for material impact is the period around the submission and any subsequent filings and approvals.
DUBLIN, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that the Company welcomes the indicated intention of its largest investor and primary lender, Perceptive Advisors, to submit a proposal that, if implemented, would facilitate the conversion of a portion of the Company’s outstanding debt and other obligations into equity.
The Company believes this strategic initiative represents a constructive step toward strengthening its balance sheet and that an equitization program, if successfully executed, could enhance the Company’s financial flexibility and support its ambitious growth objectives.
Perceptive Advisors is a leading life sciences investment firm that has continued to be a supportive and constructive investment partner to the Company through its recent transformation journey.
The Company looks forward to engaging in discussions that are mutually beneficial and aligned with the interests of all of its stakeholders, including shareholders.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, the impact of the U.S. government shut-down, our ability to achieve profitable operations in the future, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please see the Company’s website: www.trinitybiotech.com.
About Perceptive Advisors
Founded in 1999 and based in New York, NY, Perceptive Advisors is an investment management firm with approximately
| Contact: | Trinity Biotech plc | RedChip Companies Inc. |
| Susan O’Connor | Dave Gentry, CEO | |
| (353)-1-2769800 | (1)-407-644-4256 | |
| (1)-800-RED-CHIP (733-2447) | ||
| TRIB@redchip.com |
FAQ
What did Trinity Biotech (TRIB) announce on October 27, 2025 about debt-to-equity conversion?
How could Perceptive Advisors’ proposed conversion affect TRIB shareholders?
Has Trinity Biotech (TRIB) finalized terms or amounts for the proposed debt-to-equity conversion?
Will the proposed Perceptive Advisors conversion immediately change TRIB’s capital structure?
Does the TRIB announcement mention risks tied to the proposed equitization?
Where can investors find updates on Trinity Biotech (TRIB) regarding this proposal?
